NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on “Health Uncensored with Dr. Drew” on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT
NeOnc Technologies (NASDAQ:NTHI), a clinical-stage biotech company, will be featured on "Health Uncensored with Dr. Drew" on the Lifetime Network, reaching approximately 63 million TV households on September 25th at 8:00 a.m. ET/PT.
The company has achieved several key milestones, including a $50 million strategic partnership with Quazar Investment, FDA authorization for Phase II trials of NEO212, and $2.5 million in NIH grants. NeOnc's NEO™ platform technology focuses on delivering therapies across the Blood-Brain Barrier to treat brain cancer, with two drug candidates (NEO100™ and NEO212™) currently in clinical trials under FDA Fast-Track status.
NeOnc Technologies (NASDAQ:NTHI), una biotech in fase clinica, sarà presentata su «Health Uncensored with Dr. Drew» sul Lifetime Network, raggiungendo circa 63 milioni di famiglie TV il 25 settembre alle 8:00 ET/PT.
L'azienda ha raggiunto importanti traguardi, tra cui una partnership strategica da 50 milioni di dollari con Quazar Investment, l'autorizzazione FDA per gli studi di fase II di NEO212, e 2,5 milioni di dollari in sovvenzioni NIH. La piattaforma NEO™ di NeOnc si concentra sulla somministrazione di terapie attraverso la barriera emato-encefalica per trattare il cancro al cervello, con due candidati farmacologici (NEO100™ e NEO212™) attualmente in studi clinici con stato FDA Fast-Track.
NeOnc Technologies (NASDAQ:NTHI), una empresa biotecnológica en fase clínica, será presentada en «Health Uncensored with Dr. Drew» en Lifetime Network, alcanzando aproximadamente 63 millones de hogares con TV el 25 de septiembre a las 8:00 a.m. ET/PT.
La empresa ha logrado varios hitos clave, incluida una alianza estratégica de 50 millones de dólares con Quazar Investment, la autorización de la FDA para ensayos de Fase II de NEO212, y 2,5 millones de dólares en becas NIH. La plataforma tecnológica NEO™ de NeOnc se centra en entregar terapias a través de la Barrera Hematoencefálica para tratar el cáncer cerebral, con dos candidats a fármaco (NEO100™ y NEO212™) actualmente en ensayos clínicos con estatus Fast-Track de la FDA.
네온크 테크놀로지스(나스닥:NTHI), 임상 단계의 바이오텍 기업이 Lifetime Network의 “Health Uncensored with Dr. Drew”에 소개되며 9월 25일 동부표준시/태평양표준시 기준 오전 8시(ET/PT)에 약 6300만 가구에 도달합니다.
회사는 Quazar Investment와의 5천만 달러 규모의 전략적 파트너십을 포함한 주요 이정표를 달성했으며 NEO212의 2상 임상시험에 대한 FDA 승인을 받고 NIH 보조금 250만 달러를 받았습니다. NeOnc의 NEO™ 플랫폼은 혈액-뇌 장벽을 넘어 뇌암 치료를 위한 치료를 전달하는 데 집중하며, 현재 FDA Fast-Track 상태로 임상시험 중인 두 가지 후보 약물(NEO100™ 및 NEO212™)이 있습니다.
NeOnc Technologies (NASDAQ:NTHI), une société biotechnologique en phase clinique, sera présentée sur « Health Uncensored with Dr. Drew » sur le réseau Lifetime, atteignant environ 63 millions de foyers TV le 25 septembre à 8 h 00 HE/PT.
L'entreprise a atteint plusieurs jalons clés, notamment un partenariat stratégique de 50 millions de dollars avec Quazar Investment, l'autorisation de la FDA pour les essais de phase II de NEO212, et 2,5 millions de dollars de bourses NIH. La plateforme NEO™ de NeOnc se concentre sur l'administration de thérapies à travers la barrière hémato-encéphalique pour traiter le cancer du cerveau, avec deux candidats-médicaments (NEO100™ et NEO212™) actuellement en essais cliniques sous statut Fast-Track de la FDA.
NeOnc Technologies (NASDAQ:NTHI), ein klinisch fortgeschrittenes Biotech-Unternehmen, wird am „Health Uncensored with Dr. Drew“ auf dem Lifetime Network vorgestellt und erreicht ca. 63 Millionen TV-Haushalte am 25. September um 8:00 Uhr ET/PT.
Das Unternehmen hat mehrere wichtige Meilensteine erreicht, darunter eine Strategische Partnerschaft über 50 Mio. USD mit Quazar Investment, FDA-Zulassung für Phase-II-Studien von NEO212 und 2,5 Mio. USD NIH-Zuschüsse. NeOncs NEO™-Plattform konzentriert sich darauf, Therapien über die Blut-Hirn-Schranke zu liefern, um Hirntumore zu behandeln, mit zwei Wirkstoffkandidaten (NEO100™ und NEO212™), die derzeit in klinischen Studien mit FDA-Fast-Track-Status sind.
NeOnc Technologies (NASDAQ:NTHI)، شركة تكنولوجية حيوية في المرحلة السريرية، ستظهر في «Health Uncensored with Dr. Drew» على شبكة Lifetime، وتصل إلى نحو 63 مليون منزل تلفزيوني في 25 سبتمبر الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة/بتوقيت المحيط الهادئ.
حققت الشركة عدداً من المعالم الرئيسية، بما في ذلك شراكة استراتيجية بقيمة 50 مليون دولار مع Quazar Investment، وتفويض FDA لمرحلة II من تجارب NEO212، و2.5 مليون دولار من منح NIH. تركز تكنولوجيا منصة NEO™ من NeOnc على توصيل العلاجات عبر الحاجز الدموي الدماغي لعلاج سرطان الدماغ، مع وجود مرشحين دوائيين (NEO100™ وNEO212™) حاليًا في تجارب سريرية تحت وضع FDA Fast-Track.
NeOnc Technologies (NASDAQ:NTHI)，一家处于临床阶段的生物技术公司，将在 Lifetime Network 的 “Health Uncensored with Dr. Drew”节目中亮相，预计在美国东部时间/太平洋时间的9月25日8:00 a.m. 向大约6300万户电视家庭传播。
该公司已实现若干关键里程碑，包括与 Quazar Investment 的 5000万美元战略伙伴关系、FDA 对 NEO212 的 II 期试验批准，以及 250万美元 NIH 资助。NeOnc 的 NEO™ 平台技术聚焦于通过血脑屏障输送治疗手段以治疗脑癌，当前有两个候选药物（NEO100™ 和 NEO212™）处于 FDA Fast-Track 状态的临床试验中。
- Secured $50 million strategic partnership with Quazar Investment
- Received FDA authorization for Phase II Clinical Trial of NEO212
- Obtained $2.5 million in non-dilutive NIH grants
- Both drug candidates have FDA Fast-Track status
- Added to Russell Microcap® Index, increasing institutional visibility
- None.
Insights
NeOnc secures $50M partnership, advances Phase II trials with FDA authorization, and approaches data readouts for novel brain cancer treatments.
NeOnc Technologies' upcoming TV appearance serves as a platform to highlight their substantial recent progress in developing therapies that cross the blood-brain barrier (BBB) - one of the most significant challenges in treating central nervous system cancers. The $50 million strategic partnership with Quazar Investment marks a significant capital infusion that strengthens their financial position while expanding their clinical trial footprint into the GCC & MENA regions.
More critically for their clinical development timeline, NeOnc has received FDA authorization to proceed with Phase II trials for NEO212, their first-in-class oral conjugated chemotherapy candidate. This regulatory milestone, coupled with the approaching full enrollment in their NEO100-01 Phase 2a trial, positions the company for potential value-creating data readouts in early 2026.
The $2.5 million in non-dilutive NIH grants provides both additional working capital and third-party scientific validation of their approach. Their inclusion in the Russell Microcap Index is particularly meaningful as it typically drives passive investment flows and increased institutional visibility.
The company's NEO™ platform technology addresses the critical blood-brain barrier penetration challenge that has historically limited treatment efficacy for brain cancers. With both lead candidates (NEO100 and NEO212) having secured FDA Fast-Track designation, NeOnc has potential accelerated development and regulatory review pathways that could compress timelines to potential approval if clinical data proves positive.
CALABASAS, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, will be featured on Health Uncensored hosted by Dr. Drew Pinsky. The episode is scheduled to air on the Lifetime Network, available to approximately 63 million television households in the United States, on September 25th, premiering nationwide at 8:00 a.m. ET/PT. The show averages over 500,000 viewers per episode, underscoring the significant national exposure of this feature.
Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies, and Dr. Thomas Chen, CEO and Chief Medical Officer, will sit down with Dr. Drew—who earned his medical degree from the University of Southern California (USC)—to explain NeOnc’s platform technology. Viewers will also hear directly from a patient whose brain cancer is in remission, providing a firsthand account of how NeOnc’s drug candidates are designed to overcome the body’s Blood-Brain Barrier and thus have the potential to change lives.
“The Blood-Brain Barrier has long been a formidable obstacle in treating brain cancer, leaving many patients with limited options. We believe our NEO™ platform technology represents a paradigm shift, designed to carry potent therapies directly across this barrier to the tumor site,” said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. “This national platform is a timely opportunity to share our vision, highlight a patient’s incredible journey of recovery, and update the public on the significant momentum we are building as we advance our clinical programs toward key data readouts.”
The television feature comes at a pivotal time for NeOnc, which has recently achieved several transformative milestones:
$50 Million Strategic Partnership Secured – All contingencies finalized with Quazar Investment following incorporation of NuroMENA Holdings under Abu Dhabi Global Market (ADGM). This partnership will launch an advanced GCC & MENA clinical trials platform and expand NTHI’s global footprint.- Received FDA Authorization to proceed with Phase II Clinical Trial of NEO212 – a first-in-class oral chemical conjugated chemotherapy candidate for brain cancer.
- Is nearing full enrollment for its NEO100-01 Phase 2a trial, with top-line data readout anticipated in early 2026. The final patient cohort in its NEO212 Phase I trial is also on track for completion in 2025.
- Was recently added to the Russell Microcap® Index, increasing its visibility among institutional investors.
- Received
$2.5 million in non-dilutive grants from the National Institutes of Health (NIH) to advance its NEO212 program, underscoring strong external validation of its science.
NeOnc’s NEO™ drug development platform is the core of its innovation, designed to transport a variety of therapeutics across the Blood-Brain Barrier. This platform has yielded the company’s lead drug candidates, NEO100™ and NEO212™, which are currently in Phase II and Phase I human clinical trials, respectively, for treating malignant gliomas. Both therapeutics are advancing under FDA Fast-Track status, highlighting the urgent need for new treatments for these aggressive cancers.
To learn more about Health Uncensored, visit https://drdrew.com/health-uncensored-with-dr-drew/. Check your local provider for TV channel listings for the Lifetime Network.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.
The “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
info@neonc.com
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
James@haydenir.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/efaad53d-7773-4a31-a781-8ff81181b466
FAQ
When will NeOnc Technologies (NTHI) appear on Health Uncensored with Dr. Drew?
What is the value of NeOnc Technologies' strategic partnership with Quazar Investment?
What are NeOnc Technologies' main drug candidates in clinical trials?
How much grant funding did NeOnc Technologies receive from NIH?
When is NeOnc Technologies expecting top-line data from its NEO100-01 Phase 2a trial?
